1 Citation (Scopus)

Abstract

The features of chronic hepatitis B virus (HBV) related liver diseases and the aim of their therapy have briefly discussed, then treatment modalities are listed. In Hungary, between 1994 and 1996, a total of 68 patients with chronic hepatitis B have been treated with interferon (IFN). IFN resulted in complete clinical-biochemical remission in 50% of the patients, and in 32% the HBV replication was also eliminated. There are various nucleoside analogues, among them mostly famciclovir and lamivudine have been intensively studied as potentially effective treatment for HBV infection, and controlled clinical trials are in progress with these drugs. Nucleoside analogues in combination with IFN possibly improve treatment results in this disease. Various immunomodulatory agents--such as levamisole, thymosine, interleukin-2, and other cytokines--as well as the prednisolon-withdrawal induced rebound phenomenon have also been tested in HBV infection, but with no generally established benefit. A recombinant HBsAg vaccine is under investigation for therapeutic use. For end-stage HBV liver cirrhosis, liver transplantation is the only treatment, but the problem of reinfection is not still solved for more reasons.

Original languageHungarian
Pages (from-to)1462-1465
Number of pages4
JournalOrvosi Hetilap
Volume138
Issue number22 Suppl 1
Publication statusPublished - jún. 1 1997

Fingerprint

Chronic Hepatitis B
Hepatitis B virus
Interferons
Virus Diseases
Nucleosides
Therapeutics
Levamisole
Synthetic Vaccines
Lamivudine
Hungary
Controlled Clinical Trials
Therapeutic Uses
Hepatitis B Surface Antigens
Virus Replication
Prednisolone
Liver Cirrhosis
Liver Transplantation
Interleukin-2
Liver Diseases
Cytokines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Telegdy, L. (1997). A krónikus B hepatitis kezelése. Orvosi Hetilap, 138(22 Suppl 1), 1462-1465.

A krónikus B hepatitis kezelése. / Telegdy, L.

In: Orvosi Hetilap, Vol. 138, No. 22 Suppl 1, 01.06.1997, p. 1462-1465.

Research output: Article

Telegdy, L 1997, 'A krónikus B hepatitis kezelése.', Orvosi Hetilap, vol. 138, no. 22 Suppl 1, pp. 1462-1465.
Telegdy L. A krónikus B hepatitis kezelése. Orvosi Hetilap. 1997 jún. 1;138(22 Suppl 1):1462-1465.
Telegdy, L. / A krónikus B hepatitis kezelése. In: Orvosi Hetilap. 1997 ; Vol. 138, No. 22 Suppl 1. pp. 1462-1465.
@article{67da86a143414c7e9c8d3cd56eefcdf4,
title = "A kr{\'o}nikus B hepatitis kezel{\'e}se.",
abstract = "The features of chronic hepatitis B virus (HBV) related liver diseases and the aim of their therapy have briefly discussed, then treatment modalities are listed. In Hungary, between 1994 and 1996, a total of 68 patients with chronic hepatitis B have been treated with interferon (IFN). IFN resulted in complete clinical-biochemical remission in 50{\%} of the patients, and in 32{\%} the HBV replication was also eliminated. There are various nucleoside analogues, among them mostly famciclovir and lamivudine have been intensively studied as potentially effective treatment for HBV infection, and controlled clinical trials are in progress with these drugs. Nucleoside analogues in combination with IFN possibly improve treatment results in this disease. Various immunomodulatory agents--such as levamisole, thymosine, interleukin-2, and other cytokines--as well as the prednisolon-withdrawal induced rebound phenomenon have also been tested in HBV infection, but with no generally established benefit. A recombinant HBsAg vaccine is under investigation for therapeutic use. For end-stage HBV liver cirrhosis, liver transplantation is the only treatment, but the problem of reinfection is not still solved for more reasons.",
author = "L. Telegdy",
year = "1997",
month = "6",
day = "1",
language = "Hungarian",
volume = "138",
pages = "1462--1465",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22 Suppl 1",

}

TY - JOUR

T1 - A krónikus B hepatitis kezelése.

AU - Telegdy, L.

PY - 1997/6/1

Y1 - 1997/6/1

N2 - The features of chronic hepatitis B virus (HBV) related liver diseases and the aim of their therapy have briefly discussed, then treatment modalities are listed. In Hungary, between 1994 and 1996, a total of 68 patients with chronic hepatitis B have been treated with interferon (IFN). IFN resulted in complete clinical-biochemical remission in 50% of the patients, and in 32% the HBV replication was also eliminated. There are various nucleoside analogues, among them mostly famciclovir and lamivudine have been intensively studied as potentially effective treatment for HBV infection, and controlled clinical trials are in progress with these drugs. Nucleoside analogues in combination with IFN possibly improve treatment results in this disease. Various immunomodulatory agents--such as levamisole, thymosine, interleukin-2, and other cytokines--as well as the prednisolon-withdrawal induced rebound phenomenon have also been tested in HBV infection, but with no generally established benefit. A recombinant HBsAg vaccine is under investigation for therapeutic use. For end-stage HBV liver cirrhosis, liver transplantation is the only treatment, but the problem of reinfection is not still solved for more reasons.

AB - The features of chronic hepatitis B virus (HBV) related liver diseases and the aim of their therapy have briefly discussed, then treatment modalities are listed. In Hungary, between 1994 and 1996, a total of 68 patients with chronic hepatitis B have been treated with interferon (IFN). IFN resulted in complete clinical-biochemical remission in 50% of the patients, and in 32% the HBV replication was also eliminated. There are various nucleoside analogues, among them mostly famciclovir and lamivudine have been intensively studied as potentially effective treatment for HBV infection, and controlled clinical trials are in progress with these drugs. Nucleoside analogues in combination with IFN possibly improve treatment results in this disease. Various immunomodulatory agents--such as levamisole, thymosine, interleukin-2, and other cytokines--as well as the prednisolon-withdrawal induced rebound phenomenon have also been tested in HBV infection, but with no generally established benefit. A recombinant HBsAg vaccine is under investigation for therapeutic use. For end-stage HBV liver cirrhosis, liver transplantation is the only treatment, but the problem of reinfection is not still solved for more reasons.

UR - http://www.scopus.com/inward/record.url?scp=0031154592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031154592&partnerID=8YFLogxK

M3 - Article

C2 - 9221375

AN - SCOPUS:0031154592

VL - 138

SP - 1462

EP - 1465

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22 Suppl 1

ER -